When comparing the MRD-guided AIEOP-BFM ALL 2000 and DCOG ALL10 trials, the latter resulted in a higher EFS and used less cyclophosphamide and cytarabine, but more glucocorticoids, vincristine, asparaginase, LD-MTX and anthracyclines. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.